Novartis stock heads into the open after a 2.2% drop
Published on 09/11/2026 at 07:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
At the close on September 10, 2026, Novartis stock ended the session at CHF 108.60 on the SIX Swiss Exchange, down 2.2 percent for the day. The shares traded between CHF 108.07 and CHF 111.69 on September 10, 2026, on volume of about 11.50 million shares, while the Swiss Market Index moved more moderately over the same period.
September 10, 2026 in numbers
Novartis AG (ISIN CH0012005267) closed at CHF 108.60 on the SIX Swiss Exchange on September 10, 2026, compared with an opening price of CHF 111.66 and an intraday range between CHF 108.07 and CHF 111.69, according to quote data from Techgraph as of September 10, 2026. Per the same overview, around 11.50 million Novartis shares changed hands that session, with the 52-week range standing between CHF 86.90 and CHF 135.56 as of September 10, 2026, placing the latest close roughly CHF 21 below the 52-week high and CHF 22 above the 52-week low. The daily decline of 2.2 percent on September 10, 2026 left the stock still above the lows hit earlier in the week, while the broader Swiss Market Index showed smaller moves that day.
The session followed a sharp sell-off earlier in the week after back-to-back failures in late-stage clinical trials. As Reuters reported on September 10, 2026, a major shareholder called for a shake-up of Novartis board to improve corporate governance after the shares suffered a record fall earlier in the week following drug trial setbacks. In a separate market wrap, Investing.com noted on September 10, 2026 that Novartis stock gained around 1.3 percent intraday to CHF 113.14 in a tentative recovery after suffering one of its steepest single-session declines in over two decades, driven by the late-stage clinical trial failures that erased billions of francs in market value.
Today's focus for September 11, 2026
Looking ahead to today's session on September 11, 2026, investors are set to weigh the ongoing fallout from the recent trial failures and the governance debate triggered by the major shareholder's call for a board overhaul, as highlighted by Reuters on September 10, 2026. In addition, broader market sentiment toward pharmaceutical and healthcare names may be influenced today by the continuing discussion of clinical trial risk and regulatory scrutiny, factors that have featured prominently in recent commentary such as the recovery note from Investing.com dated September 10, 2026. No specific company earnings release or shareholder meeting for Novartis is scheduled for today in the available recent disclosures, so attention ahead of the open on September 11, 2026 is likely to center on how the stock trades relative to its recent volatility, its position within the CHF 86.90 to CHF 135.56 52-week range, and the broader performance of the Swiss Market Index and global healthcare peers.
